Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-09-25

Clinical Trial Update: Effect of LY450139 on the Long Term Progression of Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of LY450139 (semagacestat) for Alzheimer's disease has completed; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LY450139 (semagacestat) (semagacestat)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer's Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-09-25